Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trialMatteo Della Porta, Uwe Platzbecker, Guillermo Garcia‐Manero et al.|The Lancet Haematology|2024Cited by 50
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trialMaria Domenica Cappellini, Alì Taher, Vip Viprakasit et al.|The Lancet Haematology|2025Cited by 17
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS TrialGuillermo Garcia‐Manero, Uwe Platzbecker, Valeria Santini et al.|Advances in Therapy|2025Cited by 4
Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent-Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS TrialGuillermo Garcia‐Manero, Uwe Platzbecker, Valeria Santini et al.|Blood|2024Cited by 4
Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilusAmer M. Zeidan, Matteo Della Porta, María Diez‐Campelo et al.|Blood|2025Cited by 1